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Regulation of renal erythropoietin 
expression by the skin
Response to hypoxia involves increased synthesis of erythropoietin 
(EPO), an erythropoietic hormone chieﬂy produced by the kidney 
and liver. EPO also has nonerythropoietic roles, as cells outside of 
the hematopoietic system — neurons, vascular endothelial cells, 
and cardiac myocytes — express the EPO receptor. In addition, 
recent work has shown that EPO and its receptors are key factors 
in ventilatory responses to hypoxia. Changes in renal blood ﬂow 
can inﬂuence renal oxygen levels, which change EPO expression 
by acting on oxygen-sensing cells. The molecular mechanisms 
for this involve hypoxia-inducible transcription factors (HIFs), 
which are the primary modulators of the transcriptional hypoxic 
response and are, in turn, negatively regulated by the von Hippel-
Lindau (VHL) factor. Under normoxic conditions, the VHL gene 
acts to ubiquitinate the HIF transcription factors and induce their 
turnover by oxygen-dependent hydroxylases. The skin acts as an 
essential buﬀer against the environment, protecting internal tissues 
by conserving water, guarding against pathogens, and respond-
ing to environmental stresses such as changes in temperature. 
Although the skin has an important respiratory function in 
amphibians, this role has been relatively unexplored in mammals. 
Mammalian skin may be unique as a tissue in that it is not solely 
dependent on cardiopulmonary delivery of oxygen and can utilize 
oxygen directly from the atmosphere. In addition, when the air 
overlying the epidermis becomes hypoxic, keratinocytes induce 
vasodilation in the underlying dermal vasculature. In recent and 
fascinating work, Boutin et al. examined whether the skin plays 
a role in the systemic response to hypoxia. They reported that 
epidermal deletion of the hypoxia-responsive transcription factor 
HIF-1α inhibited renal EPO synthesis in response to hypoxia and 
lowered plasma EPO concentration (Figure). Conversely, mice 
with an epidermal deletion of the VHL factor, a negative regula-
tor of HIF, had increased EPO synthesis and polycythemia. The 
authors also reported that an increase in systemic EPO expression 
was dependent on the release of nitric oxide by the skin, which 
perhaps acted on EPO synthesis by changing blood ﬂow to the liver 
and kidneys. Regardless of the exact mechanism, these extremely 
Contaminated heparin associated 
with adverse events and activation 
of the contact system
A total of 81 deaths related to allergic reactions or hypoten-
sion in patients receiving heparin were reported to the United 
States Food and Drug Administration (FDA) between 1 January 
2007 and 13 April 2008. These events were initially linked to 
heparin lots manufactured by Baxter Healthcare, resulting in 
recall of their products. The contaminant was identiﬁed as an 
unusual oversulfated form of chondroitin sulfate (OSCS). A 
new report by Kishimoto et al. that investigates the mechanism 
by which this contaminant resulted in severe clinical outcomes 
reminds nephrologists of the importance of voluntary reporting 
of adverse events to the FDA.
Lots of heparin associated with the adverse events, as well 
as control lots, were procured from the FDA and screened in 
a blinded fashion for the presence of OSCS and any biologic 
activity that could link the contaminant to adverse events. 
The OSCS found in the contaminated lots of unfractionated 
heparin directly activated the kinin–kallikrein pathway in 
human plasma (Figure) to an extent similar to that seen with 
the OSCS reference standard, leading to generation of brady-
kinin. OSCS also generated the anaphylatoxins C3a and C5a. 
OSCS-containing heparin and synthetically derived OSCS both 
induced hypotension associated with kallikrein activation when 
administered by infusion in swine.
The rapid response by the groups and agencies to identify 
the existence and etiology of the problem occurred because 
physicians and health-care workers participated in the volun-
tary reporting system for adverse events. Health-care profes-
sionals and consumers should report adverse events noted in 
the course of clinical care that they suspect are associated with 
the use of an FDA-regulated drug, biologic, medical device, or 
dietary supplement. Deﬁnitive proof of the relationship to the 
event is not required, nor is it assumed. Clinicians need only 
suspect. Directions on how to use the FDA 3500 MedWatch 
form can be found at http://www.fda.gov/medwatch/report/
hcp.htm. (N Engl J Med advance online publication, 23 April 
2008; doi:10.1056/NEJMoa0803200)
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Effect of OSCS on kallikrein activity. UFH, unfractionated heparin.  
OD, optical density.
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Left: Plasma EPO following hypoxic exposure for 14 hours at 9% 
oxygen is significantly reduced in mice lacking HIF-1α in the epidermis 
(K14cre-HIF-1α+f/+f ). Right: In these mice, renal EPO mRNA expression 
is reduced to normoxic levels in hypoxic conditions. WT, wild type.
Kidney International (2008) 74          13
journal  c lub
interesting results open unexpected avenues of research and sug-
gest novel mechanisms for induction of EPO expression. (Cell 
2008; 133: 223–234; doi:10.1016/j.cell.2008.02.038)
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Pitfalls of measuring total blood 
calcium in patients with chronic 
kidney disease
Both the National Kidney Foundation Kidney Disease Outcomes 
Quality Initiative (K/DOQI) guidelines and the Kidney Disease: 
Improving Global Outcomes (KDIGO) position statement rec-
ommend that blood calcium be measured regularly in patients 
with chronic kidney disease (CKD). The need to correct total cal-
cium for the presence of hypoalbuminuria to estimate whether 
ionized calcium levels are likely appropriate is well known. A new 
study compares the performances of non-corrected and albumin-
corrected total calcium in predicting low, normal, and high serum 
ionized calcium concentrations.
Gauci et al. correlated non-corrected and albumin-corrected 
total calcium and ionized calcium in 691 consecutive patients 
with stages 3 to 5 CKD. Correlations between these parameters 
two at a time revealed correlation coeﬃcients of between 0.46 and 
0.55. When ionized calcium was below the lower limit of normal, 
the sensitivity of an albumin-corrected formula in detecting this 
abnormality was approximately 29%–36%. Similarly, when ionized 
calcium was above the upper limit of normal, the sensitivity of an 
albumin-corrected formula in detecting this abnormality was only 
21.4%. The risk for miscategorizing the estimate of ionized calcium 
using a formula correcting total calcium for hypoalbuminuria 
independently increased in the presence of a lower total CO2 con-
centration, a lower albumin concentration, or older age.
This straightforward study seeks to conﬁrm our assumptions 
about the reliability of albumin-corrected total calcium in pre-
dicting deviations in ionized calcium. Albumin-corrected total 
calcium does not predict ionized calcium as well as or better than 
non-corrected total calcium. While identiﬁcation of persons with 
ionized calcium levels outside normal limits is highly speciﬁc, the 
low sensitivity suggests that reliance on total calcium values cor-
rected for albumin levels could result in failure to identify patients 
with abnormal values that may require intervention. (J Am Soc 
Nephrol advance online publication, 9 April 2008; doi:10.1681/
ASN.2007040449)
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Fasudil, a RhoA kinase inhibitor, 
inhibits progression of crescentic 
glomerulonephritis
Crescentic glomerulonephritis (GN), a manifestation of severe 
glomerular injury, is associated with poor clinical outcomes. It is 
observed in a variety of GN of immune origin — in particular, 
anti-glomerular basement membrane disease and class IV lupus 
nephritis. Although the pathogenesis of glomerular crescents 
remains unknown, cytoskeletal changes of podocytes are critically 
involved in the pathogenesis of GN. Small GTPases of the Rho fam-
ily are key regulators of the cellular cytoskeleton. RhoA, in particu-
lar, is involved in the regulation of stress ﬁber and focal adhesion 
formation, cell morphology, cell aggregation, cadherin-mediated 
cell–cell adhesion, cell motility, cytokinesis, membrane ruﬄing, 
neurite retraction, microvillus formation, and smooth muscle con-
traction. It has been shown that blocking cytoskeleton rearrange-
ment using a RhoA kinase inhibitor prevents activation of nuclear 
factor-κB and Ap-1, suggesting a direct link between cytoskeleton 
and transcriptional regulation in podocytes. RhoA is activated by 
the angiotensin II (AngII) type 1 receptor (AT1R), which is part 
of the local renin–angiotensin system involved in podocyte injury 
preceding glomerular crescent formation. Suzuki and colleagues 
demonstrated previously in Fc receptor-deﬁcient mice (γ–/–) that 
inhibition of AT1R protects against crescentic glomerular injury 
with anti-glomerular basement membrane antibody (anti-GBM 
GN). Now they examine anti-GBM GN in γ–/– mice with or 
without fasudil treatment and further investigate the underlying 
mechanisms in cultured diﬀerentiated podocytes and leukocytes. 
Fasudil attenuated crescentic GN (Figure), signiﬁcantly decreased 
proteinuria, hematuria, inﬁltration of T cells and monocytes/macro-
phages and their local proliferation, and preserved podocyte-spe-
ciﬁc proteins in glomeruli, including wild-type-1 and nephrin. 
In vitro studies showed that AngII induced the downregulation 
of both nephrin and wild-type-1 expression in podocytes, which 
fasudil reversed in a dose-dependent manner. Additionally, fasudil 
blocked the AngII-induced migration of both macrophages and 
T cells. The authors also examined lipopolysaccharide-induced 
nephrotic syndrome in severe combined immunodeﬁciency dis-
ease mice and found that fasudil failed to block the development 
of proteinuria because of a B7-1-dependent podocyte injury. The 
investigators concluded that fasudil treatment inhibits crescent for-
mation and disease progression in anti-GBM GN by preventing 
AngII-induced podocyte injury and leukocyte migration. Am J 
Pathol 2008; 172: 603–614; doi:10.2353/ajpath.2008.070196) 
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Pretreatment with fasudil prevented renal injury in γ–/– mice with anti-
GBM GN. In the untreated group, crescent formation (arrows) and sclerotic 
change (arrowheads) were seen in many glomeruli, but these effects were 
absent after fasudil treatment. Tx, treatment group.
